Answers are grounded in this paper and cite their sources.
On request, and to aid others doing similar trials, we are publishing the full standard operating procedures (SOPs) for the Oxford University-sponsored trials of the ChAdOx1 nCoV-19 vaccine. Operational details about running clinical trials of COVID-19 vaccines in a pandemic are not generally available as they are contained in SOPs held at trial sites. These SOPs can provide additional insight into study conduct that assist with interpretation of the data. We have provided an additional appendix to our Article reporting the phase 1/2 findings1Folegatti PM Ewer KJ Aley PK et al.Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled.Lancet. 2020; 396: 467-478Summary Full Text Full Text PDF PubMed Scopus (1772) Google Scholar to provide this information about the key processes guiding the Oxford University-sponsored trials of the ChAdOx1 nCoV-19 vaccine. The SOPs were prepared by Susan Jackson, Susanne H Hodgson, and Hazel Morrison. I report grants from the National Institute for Health Research (NIHR), UK Research and Innovation, and CEPI, am Chair of the UK Department of Health and Social Care (DHSC) Joint Committee on Vaccination and Immunisation (JCVI), and am a member of WHO's Strategic Advisory Group of Experts (SAGE) on Immunization. I have not participated in policy discussions or decisions about COVID-19 vaccines. The views expressed in this Comment do not necessarily represent the views of DHSC, JCVI, NIHR, or WHO. The University of Oxford has entered into a partnership with AstraZeneca on COVID-19 vaccine development. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trialChAdOx1 nCoV-19 showed an acceptable safety profile, and homologous boosting increased antibody responses. These results, together with the induction of both humoral and cellular immune responses, support large-scale evaluation of this candidate vaccine in an ongoing phase 3 programme.
No takes yet. Share an insight, caveat, or question.
Andrew J. Pollard (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: